[{"id":"f4e7bfa0-b752-484d-96c0-7b0fd411e68b","acronym":"","url":"https://clinicaltrials.gov/study/NCT07144280","created_at":"2025-08-30T13:50:25.910Z","updated_at":"2025-08-30T13:50:25.910Z","phase":"Phase 3","brief_title":"A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT07144280","lead_sponsor":"Pfizer","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • PF-08046054"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 680","initiation":"Initiation: 08/22/2025","start_date":" 08/22/2025","primary_txt":" Primary completion: 03/10/2028","primary_completion_date":" 03/10/2028","study_txt":" Completion: 03/10/2032","study_completion_date":" 03/10/2032","last_update_posted":"2025-08-27"},{"id":"0b405f7d-3f61-4823-b79f-2d25bdb0eeb2","acronym":"SGNPDL1V-001","url":"https://clinicaltrials.gov/study/NCT05208762","created_at":"2023-05-26T17:05:40.425Z","updated_at":"2025-02-25T13:49:21.100Z","phase":"Phase 1","brief_title":"A Study of SGN-PDL1V in Advanced Solid Tumors","source_id_and_acronym":"NCT05208762 - SGNPDL1V-001","lead_sponsor":"Seagen Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • PF-08046054"],"overall_status":"Recruiting","enrollment":" Enrollment 315","initiation":"Initiation: 10/25/2022","start_date":" 10/25/2022","primary_txt":" Primary completion: 11/18/2027","primary_completion_date":" 11/18/2027","study_txt":" Completion: 11/17/2028","study_completion_date":" 11/17/2028","last_update_posted":"2025-02-21"}]